Passage Bio Highlights PBFT02 Progress and Extended Cash Runway

Passage Bio ( (PASG) ) has provided an announcement.

On January 12, 2026, Passage Bio updated its corporate presentation to highlight progress on PBFT02, its lead gene therapy candidate for frontotemporal dementia caused by GRN mutations (FTD-GRN), and to outline its broader strategy in neurodegenerative diseases. The materials emphasized PBFT02’s potential best-in-class profile as a one-time, cerebrospinal fluid–delivered AAV1 gene replacement therapy that raises progranulin levels, backed by nonhuman primate and mouse data showing broad CNS biodistribution, durable increases in CSF progranulin and improvements in markers of lysosomal dysfunction and neuroinflammation, as well as fast track and orphan drug designations and ongoing enrollment in the global Phase 1/2 upliFT-D trial. Passage Bio also underscored the sizable addressable market in FTD and Huntington’s disease and reported a cash runway expected to extend into the first quarter of 2027, positioning the company to advance its clinical and preclinical pipeline during a period of significant unmet need in adult-onset neurodegenerative conditions.

The most recent analyst rating on (PASG) stock is a Hold with a $19.00 price target. To see the full list of analyst forecasts on Passage Bio stock, see the PASG Stock Forecast page.

Spark’s Take on PASG Stock

According to Spark, TipRanks’ AI Analyst, PASG is a Neutral.

Score is held back primarily by weak financial fundamentals typical of a pre-revenue biotech (ongoing losses and negative free cash flow, with financing risk). Technicals are supportive due to a strong uptrend but are tempered by overbought momentum signals. Corporate updates are constructive (regulatory/process progress and runway into Q1 2027), partially offsetting the financial risk, while valuation remains constrained by unprofitability and lack of dividend.

To see Spark’s full report on PASG stock, click here.

More about Passage Bio

Passage Bio is a clinical-stage gene therapy company focused on developing one-time adeno-associated virus (AAV)-based treatments for neurodegenerative diseases. Its lead programs target frontotemporal dementia (FTD), including genetic subtypes such as FTD-GRN and FTD-C9orf72, and it is pursuing preclinical development in Huntington’s disease, concentrating on diseases with high unmet medical need in the U.S. and Europe.

Average Trading Volume: 53,358

Technical Sentiment Signal: Buy

Current Market Cap: $57.2M

For an in-depth examination of PASG stock, go to TipRanks’ Overview page.